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Ever since the discovery of the first case of chloroquine resistance along the Thai-Combodian border
in the late 1950s, Southeast Asia has played an important role as a focus for the development of drug
resistance in Plasmodium  falciparum. Although the first case of quinine resistance had been reported
much earlier from South America, the onset of chloroquine resistance marked the beginning of a new
chapter in the history of malaria in Southeast Asia and by 1973 chloroquine finally had to be replaced
by the combination of sulphadoxine and pyrimethamine (SP) as first line drug for the treatment of
uncomplicated malaria in Thailand and more than 10  African countries have also switched their first
line drug to SP. In 1985, eventually SP was replaced by mefloquine. The rapid development of resistance
to this new drug leads to the introduction of artemisinin as a combination drug in the mid-1990s.
It is mandatory to mention here that therapeutic regimens for prevention and treatment of chloroquine-
resistant P. falciparum are associated with higher costs and side-effects compared to chloroquine.
Additionally, some of these alternative treatments are associated with more side-effects, take longer
time for cure and are more difficult to comply with than chloroquine.
Urgent efforts are needed to identify effective, affordable, alternative antimalarial regimens. Molecular
markers for antimalarial resistance have been identified, including pfmdr-1 and pfcrt polymorphisms
associated with chloroquine resistance and dhfr and dhps polymorphisms associated with SP resistance.
Polymorphisms in pfmdr-1 may also be associated with resistance to chloroquine, mefloquine and
artemisinin. Use of such genetic information for the early detection of resistance foci and future
monitoring of drug resistant malaria is a potentially useful epidemiological tool, in conjunction with
the conventional in vitro and in vivo drug sensitivity assessments. The purpose of this review is to
describe the state of knowledge regarding drug resistant malaria and to outline the changing patterns
of drug resistance including its determinants, current status in diverse geographical areas, molecular
markers and their implications to limit the advent, spread and intensification of drug resistant malaria.
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The magnitude of malaria in terms of morbidity and
mortality in humans makes it a major public health
problem in tropical and subtropical countries. Despite
the impressive initial results of the National Malaria
Control and Eradication Programmes initiated in
1950s, there was a complete failure to eradicate ma-
laria in many countries due to technical, operational
and socio-economical difficulties, which led to resur-
gence of malaria in many parts of the world. The con-
trol programme has been hampered by the  spread ofJ  VECT  BORNE  DIS  41, SEPTEMBER & DECEMBER  2004 46
drug resistance in parasite and insecticide resistance in
mosquito vectors1.
It is estimated that 300–500 million people are infect-
ed worldwide annually and 1.5–2.7 million people die
of malaria every year, which include approximately
one million children under the age of five years. Sub-
Saharan Africa and countries in tropical Africa ac-
count for more than 90% of total malaria incidence
and great majority of deaths due to malaria. In India,
over the past two decades, malaria incidence has
been fluctuating between 2 to 3 million cases per
year2,3.  India contributes 40% of all cases outside
Africa. In 1972, Plasmodium falciparum incidence
was 9.3%, which increased to 43.4% in 19914.  The
percentage of P. falciparum infections has, however,
decreased from 43.4 to 38.89% in 19962. Urban ma-
laria is a complicated and severe problem in India and
more than 130 towns spread across 17 states are
covered by the urban malaria control scheme. The sit-
uation has been further complicated by the spread of
the strains of the plasmodium species, which are resis-
tant to chloroquine and other antimalarial drugs.
Drugs used in treatment
Chemotherapy has traditionally played an important
role in the treatment and control of malaria. Quinoline
containing antimalarial components are the most effec-
tive drugs for malaria chemotherapy. This group of
compounds has evolved from the structural modifica-
tion of quinine and includes 4-aminoquinoline com-
pounds such as chloroquine and mefloquine of which
former is more effective, cheap, safe and commonly
available drug.
The dihydrofolate reductase inhibitors include progua-
nil, chloroproguanil, pyrimethamine and trimethoprime
and sulfa drugs like dapsone, sulfalene, sulfamethox-
azole and sulfadoxine. These drugs are used in combi-
nations. The classical such combination is sulphadox-
ine and pyrimethamine (SP) used as first line drug in
Thailand and other parts of the world. Tetracycline
and its derivatives such as doxycycline are very potent
antimalarials and are used for both treatment and pro-
phylaxis. In areas where response to quinine has dete-
riorated, tetracyclines are often used in combination
with quinine to improve cure rates.
The other useful antimalrials are Artemisinin com-
pounds synthesised from the plant Artemisia annua.
These compounds (artesunate, artemether, arteether)
are most effective antimalarials and seem to have ef-
fect on protein synthesis by the malaria parasite.
These are used for the treatment of severe malaria and
have shown very rapid parasite clearance in compari-
son to quinine compounds. Artemisinin and meflo-
quine combination is being used in some southeast
Asian countries, for the treatment of uncomplicated
malaria, where the multi drug resistant strains of P. fal-
ciparum are prevalent5.
Current status of drug resistant malaria world-
wide and in India
Drug resistant malaria has become a major problem in
malaria control. Resistance in vivo has been reported
against almost all antimalarial drugs except Artemisinin
and its derivatives6,7.  Resistance to antimalarials has
been reported in both P. falciparum and P. vivax.
Drug resistance in P. falciparum is not confined to
chloroquine alone, but also to the other currently used
antimalarials and is widespread.
Chloroquine
Chloroquine resistant P. falciparum malaria has been
reported from wherever falciparum malaria is endemic
except in central America8, Carribean Hisparivala Is-
land and some parts of middle east and central Asia9.
Resistance to chloroquine in P. falciparum first ap-
peared virtually simultaneously in Southeast Asia
(Thai-Cambodian border) and South America (Co-
lombia) in late 1950s10–12. Since then chloroquine re-
sistance has spread far beyond the first focus and is
now found in all parts of the world where malaria is
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spread in all endemic areas of South America by
1970 and almost all in Asia and Oceania by 198913.
Chloroquine resistance in Africa was first reported in
the eastern part in 197812,13, which then spread to the
central and southern parts before arriving in west Afri-
ca in 198313,14. By 1989 chloroquine resistance was
widespread in sub-Saharan Africal3. The severity of
resistance in west and central Africa was less than in
east Africa, but even in west Africa, its intensity varies
from an advanced stage with severe effects on mor-
bidity and mortality in focal areas of Senegal15 to a
moderate degree in Ghanal6, Cameroon17 and at a
low level in Malil8.
In India chloroquine resistance was first detected in
1973 in Karbi-Anglong district in Assam19 and in
1974 in Nowgong district of Assam. Gradually it has
spread towards the west and south, covering almost
the entire country20. Currently the chloroquine resis-
tance is severe in northeast and southeastern regions
in India with high morbidity and mortality. Resistance
is currently less severe in north21, northwest and cen-
tral parts of India, southern part of India is affected
with moderate degree of resistance. Chloroquine re-
sistance in P. vivax was noted for the first time in
Papua New Guinea22 and from there it has spread to
other parts of the world. From India also there are
now several reports of chloroquine resistance in P.
vivax23–25. Resistance in P. vivax is more serious as
hypnozoites will cause relapse of resistant parasites
and P. vivax is a mixture of various strains with re-
spect to incubation period, relapsing pattern and re-
sponse to primaquine26 since sulpha drugs are not ef-
fective in its treatment.
Sulphadoxine-Pyrimethamine (SP)
Since early 1960s the increasing chloroquine resis-
tance has lead to a significant increase in mortality27.
The sulphadoxine-pyrimethamine combination was
used as a drug of choice to treat chloroquine resistant
malaria. Resistance to SP was first described from the
Thai-Cambodian border in 1960s28. Since then SP re-
sistance has been reported from large parts of South-
east Asia, southern China and Amazon basin9,29,30.
Low degree of resistance is found in Pacific Coast of
South America, southern Asia, east of Iran and western
Oceania31. In Africa, SP resistance was detected in the
late 1980s, which has since spread more in the east
than in the west. In east Africa, high percentages of
R-II /R-III responses have been documented in chil-
dren in an endemic area of Tanzania32. In India resis-
tance to sulpha drugs has been reported from P. falci-
parum predominated areas like northeast states and
Orissa. Resistance in P. falciparum to SP combination
was first detected in Delhi in 198733. Resistance is like-
ly to progress geographically and in intensity at an
alarming rate if nothing is done to interrupt its course.
Quinine
The first case of quinine resistance was reported from
South America nearly a century ago. It was observed
from Thai-Cambodian border in mid 1960s14. The
clinical resistance to quinine therapy has been noticed
sporadically in Southeast Asia and western Oceania.
It is less frequent in South America34 and Africa35.
The widespread use of quinine in Thailand in the early
1980s could be the reason for development of signifi-
cant resistance36. Therefore, since the last two de-
cades this drug has been used in combination with tet-
racycline or doxycycline to enhance its effectiveness.
In India resistance has emerged against quinine in
northeastern states and Kolar district in Karnataka37.
Mefloquine
Mefloquine resistance was first observed in late 1980s
near the Thai-Cambodian border38,39. It is frequent in
some parts of Southeast Asia and has been reported
in the Amazon region of South America and sporadi-
cally in Africa40. Resistance in P. falciparum to
mefloquine in India was detected in Surat district in
Gujarat state41.
Artemisinin
Artemisinin and its derivatives are the newest and
most effective antimalarial drugs. These drugs affectJ  VECT  BORNE  DIS  41, SEPTEMBER & DECEMBER  2004 48
the protein synthesis of the parasite. Except in an ani-
mal model, so far there has not been any solid evi-
dence of artemisinin resistance reported from any part
of the world.
Determination of drug resistance
Drug resistance by malaria parasites has been defined
as the ability of a parasite strain to survive or multiply
despite the administration and absorption of a drug
when given in doses equal to or higher than those nor-
mally recommended and within the limits of tolerance
of the subject42.  This definition may be applied to the
response of the parasite to antimalarial drugs used as
schizontocides, gametocytocides or sporontocides.
The drug resistance in the parasite can be determined
either in vivo or by in vitro drug susceptibility tests42.
In vivo tests: Soon after the reports of cases of chlo-
roquine resistance in South America and Thailand in
early 1960s, WHO established methods for determi-
nation of drug resistance42.  In vivo tests are based
on the observation of parasite response in the patients
to a fixed dose of a drug within the limits of tolerabili-
ty12,  one of the key characteristics of in vivo test in
the interplay between host and parasite.  Decreased
therapeutic efficacy of a drug can be marked by im-
mune clearance of parasite in patients with a high de-
gree of acquired immunity43.
The assessment of  in vivo drug response of  P.
falciparum to antimalarials require prolonged peri-
ods of follow-up (28 days) and seclusion of patients in
screened rooms to prevent the possibility of reinfec-
tion.  In 1990, WHO introduced a modified protocol,
involving shorter period of follow-up (7–14 days)
without seclusion, under the assumption that reap-
pearance of parasites in peripheral blood within 14
days of treatment is more likely due to recrudescence
than reinfeciton44.  Traditionally response to treatment
was categorised according to the WHO criteria purely
on parasitological ground as sensitive, R-I, R-II and
R-III45 level of resistance.  Later modifications are
based on adequate clinical response, early and late
treatment failure.  The test procedure is based on a
14-day follow-up with clinical, parasitological, haema-
tocrit and fever assessment on Day 0, 3, 7 and 142.
In vitro tests: The problem related with the assess-
ment of antimalarial drug resistance in vivo has led to
the introduction of a number of in vitro tests for the
measurement of antimalarial drug susceptibility in the
late 1970s. Traditionally two types of in vitro assays
are commonly used, WHO schizont maturation assay
and the isotopic micro test. These tests are based on
the estimation of the parasite metabolic process in
short- or long-term culture. The data derived from in
vitro tests have to be interpreted in relation to the in
vivo and pharmacological tests to determine individual
susceptibility levels for the drug tested. From the point
of view of a researcher interested in pure drug resis-
tance, in vitro tests avoid many of the confounding
factors, which influence the in vivo test, by removing
parasites from the host and placing them in a con-
trolled experimental environment. These tests more
accurately reflect the intrinsic antimalarial drug
resistance3l. Multiple tests can be performed on iso-
lates and response to several drugs can be assessed
simultaneously3l. The correlation of in vitro response
with clinical response in patients is neither clear nor
consistent and the correlation appears to depend on
the level of acquired immunity within the population
being tested. All results obtained from in vitro tests
have, therefore, to be put in relation to clinical findings
while determining the cut-off points for resistance and
when the results are used to develop treatment guide-
lines. The in vitro assays not only yield quantitative
results, but also determine the phenotype of the para-
site independently of the immune and physiopathologi-
cal status of the host. In addition both assays have a
number of individual drawbacks, which may limit their
usefulness.
Mechanisms of antimalarial resistance
Plasmodium parasite has extremely complex genome
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cro environments in different hosts and the metabolic
changes they require illustrates the difficulty in studying
the exact modes of action of the antimalarial drugs on
parasite metabolism46. In general, resistance appears
to occur through spontaneous mutations that confer
reduced sensitivity to a given drug or class of drugs31.
Resistance also develops more quickly where a large
population of parasites are exposed to drug pressure
since it will remove sensitive parasites, while resistant
parasite would survive.
In order to appropriate the physical nature of resis-
tance, it is necessary to look in more detail at the me-
tabolism of the parasite and the mode of action of the
antimalarial drugs. Intra-erythrocytic stage of malaria
parasite ingests haemoglobin into its food vacuoles.
Here exopeptidases and endopeptidases break-down
haemoglobin into haemozoin pigment of which the cy-
totoxicity of ferriprotoporphyrin IX is a major compo-
nent47. The haemebinder protein (synthesised by para-
site) sequester the ferriprotoporphyrin IX into the inert
haemaozoin complex to protect the plasmodium mem-
branes from damage. It is now appropriate to discuss
a number of antimalarials and apparent adaptation.
Chloroquine
Chloroquine is the drug that has been most studied but
its mechanism of action still remains to be elucidated.
The mechanism of the antimalarial action of quinoline
containing drugs (like chloroquine) has been investigat-
ed by many workers and several therapeutic targets
have been suggested. Most of the drug targets are loc-
alised in the acid food vacuole of the parasite 48,49. It
is believed that resistance of P. falciparum to chloro-
quine is due to increased capacity for the parasite to
expel chloroquine at a rate that does not allow chloro-
quine to reach levels required for inhibition of heame-
polymerization50. This chloroquine efflux occurs at a
rate 40 to 50 fold faster among resistant parasites than
that in sensitive ones48. Further, evidence supporting
this mechanism is provided by the fact that chloroquine
resistance would be reversed by drugs which interfere
with this efflux system51 but the biochemical basis of
this efflux is a matter of debate. The efflux of chloro-
quine and in fact the entire chloroquine resistant phe-
notype can be reversed with Ca+ channel blocker,
such as verapamil and dilitazem48,51.
Current molecular studies of P. falciparum isolates
suggest that few gene loci are associated with chloro-
quine resistance to P. falciparum. These genes have
been named as pfmdr-1 & 2, pfcrt. Pfmdr-1 gene lo-
cated on chromosome-5 and coding for P-glycopro-
tein homologne-1 (Pgh-1) has generated interest in
resistance to chloroquine and other antimalarials.
Studies conducted in different geographical areas of
the world suggest that the point mutation of aspartic
acid to tyrocine in codon 86 (A-86 to T-86) is associ-
ated with chloroquine resistance18,52–55. Several other
pfmdr-1  polymorphisms—Phe 184, Cys 1034,
Asp1042 and Tyr 1246 have been implicated to vary-
ing degrees in chloroquine resistance. Another locus
governing chloroquine resistance has been identified
on chromosome 7 and encodes a transmembrane pro-
tein in a digestive vacuole of malaria parasites56. Sets
of point mutations in pfcrt gene have been found to be
associated with in vitro chloroquine resistance in P.
falciparum from Africa, South America and South-
east Asia57. Djimde et al18 found that the substitution
of thyroxine (T76) for lysine (K76) at codon 76 was
present in all chloroquine resistant isolates and absent
in all sensitive isolates.
Antifolate combination drug resistance
The antifolate compounds like sulphadoxine-py-
rimethamine inhibit the action of dehydrofolate reduc-
tase (DHFR) while sulphones and sulphonamide com-
pounds inhibit the action of dihydropteroate synthase45
(DHPS). The dehydrofolate reductase enzymes of re-
sistant strains bind to pyrimethamine 400–800 fold
less readily than to the enzymes of drug sensitive
strains58. The molecular basis of resistance to SP is
the best characterised one. Specific gene mutations
encoding for resistance to DHFR and DHPS have
been identified. Point mutations in the five codons of
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resistance by decreasing binding affinity of the en-
zyme. Serine to alanine at codon 436 or phenylala-
nine; alanine to glycine at codon 437; lysine to glutam-
ic acid at codon 540; alanine to glycine at codon 581;
alanine to serine or threonin at codon 613; Gly437
and Gly540 have been reported to occur together or
single in various parts of the world including Indone-
sia59, Malawi, Bolivia, Kenya60 and Gabon61, while
Gly581 has been observed in South America alone62.
Specific point mutation in dhfr gene is known to be
associated with pyrimethamine resistance by reduction
in drug-binding affinity of DHFR. Alanine to valine at
codon 16, aspargine to isoleucine at codon 51, cys-
teine to arginine at codon 59, serine to asparginine at
codon 108, threonine and isoleucine to leucine at
codon 164, this combination of mutations has been
observed in Thailand, where high level of SP resis-
tance is well recognised. The point mutation from
serine to asparginine at codon 108 is a key mutation
for pyrimethamine resistance. Additional point muta-
tions in three other codons ILe51, Arg59 and Leu164
are known to increase progressively the degree of re-
sistance. The precise relation between mutations in
dhfr and dhps genes in clinical sulphadoxine-py-
rimethamine resistance is not clear13.
Quinine
There is a suggestion that pfmdr-1 mutation associat-
ed with chloroquine resistance may also account for
reduced susceptibility to quinine34. However, the ex-
act mechanism of resistance is not clear.
Mefloquine
Molecular studies have suggested that the copy num-
ber and polymorphism of pfmdr-1 gene is associated
with mefloquine resistance. The evidence on increased
pfmdr-1 copy number for mefloquine resistance is still
not clear.
A study from Thailand has suggested that a higher
copy number confers mefloquine resistance54 but oth-
er studies did not confirm that finding from Brazil34
and Africa63. Some studies have shown increased
sensitivity to mefloquine with pfmdr-1 Tyr86 muta-
tion54, 64 suggesting a possible inverse relationship be-
tween sensitivity to mefloquine and chloroquine, while
Ser1034, Asn1042 and Asp1246 mutations were
cause of resistance to mefloquine65. These findings
strengthen the role of pfmdr-1 as the key modulator
of mefloquine resistance.
Future strategy to control drug resistant malaria
Resistance in malaria parasites to antimalarials is a big
challenge, which has been a threat to most malaria
control programmes. Although the problem of drug
resistant malaria is worldwide but severe in Africa. In
several parts of the world SP combination is being
used as a first line drug after the development of resis-
tance to chloroquine. Widespread use of SP combina-
tion has resulted in loss of sensitivity rapidly, especially
in parts of east Africa, rendering them potentially
emerging multidrug resistant areas. The future antima-
larial drug resistance and efforts to combat it is de-
fined by a number of assumptions. First, antimalarial
drug will continue to be needed long into the future.
No strategy in existence or in development, short of
an unforeseen scientific breakthrough or complete
eradication, is likely to be 100% effective in prevent-
ing malaria infection. Secondly, as long as the drugs
are used, the chance of resistance development. Then
P. falciparum has developed resistance to nearly all
available antimalarial drugs and it is very likely that the
parasite will eventually develop resistance to any drug
that is used widely. Thirdly, development of new drugs
takes longer time than the development of parasite re-
sistance.
The progress of multidrug resistance is an alarming
feature, which further hampers the antimalarial control
strategy. For the management of multidrug resistant
malaria, use of antimalarial drugs in combination may
be helpful. The advantages and drawbacks of each
candidate regimen must carefully be considered for
specific endemic areas. The choice may affect future
drug policies and ability to prevent epidemics and to
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The form of prophylaxis, which may become avail-
able, is a malaria vaccine. Several trials are currently
underway and work has been progressing for several
years on this important possibility. Unfortunately, ma-
laria parasite is not easy for the immune system to deal
with via antibodies or cytotoxic T-cells, because it
survives within human RBCs, keeping it out of the
macrophages and antibodies. The sporozoite stage is
easy for the immune system to tackle but they are
transient and present in high numbers that some are
bound to infect host cells before being caught. How-
ever, a vaccine is difficult to produce due to the pres-
ence of antigenic polymorphism in most of the vaccine
candidate antigens. Genetic diversity within the differ-
ent species of parasites is a major reason as to why
the parasite survives despite the ability of their host to
mount immune responses, which are effective in elimi-
nating a particular infection. The slow development of
immunity in people living in areas where malaria is en-
demic is consistent with the hypothesis that effective
immunity only develops after exposure to a large num-
ber of genetically different parasite strains. The current
clinical trials of malaria vaccines (based on different
stage specific antigens) seen to be encouraging.
In recent years there has been a great progress in un-
derstanding the molecular basis of drug resistance in
P. falciparum. Now it is known that the mutation in
dhfr and dhps genes has been implicated as the cause
of SP resistance. The pfcrt and pfmdr-1 genes are
the focus of studies on resistance to other drugs.
These genes strongly associated with CQ resistance
and polymorphisms alter the parasites susceptibility to
mefloquine, halofantrine, quinine and artemisinin. The
more information on the genetics of drug resistance
will help in designing the novel, improved molecular
based tools for early detection and interventions that
aim at limiting the extent of established multidrug resis-
tance and preventing new foci of drug resistance from
emerging may become possible.
In conclusion the control of drug resistant in malaria
parasites, requires reducing the overall drug pressure
through more selective use of drugs and improving the
ways the drugs are used and by prescribing the fol-
low-up practices or using drugs combination which
are inherently less likely to foster resistance or have
properties that do not facilitate development or spread
of resistant parasites.
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